FDA mulls compounding for peptides previously flagged over safety risks BioSpace The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Compounded "semaglutide" is not FDA approved semaglutide.com The FDA scheduled a hearing on peptides and the implications could be significant for prescribers and FDA to weigh easing limits on unproven peptides favored by RFK Jr. and MAHA supporters PBS News Peptides and BPC 157 for Pain: PainExam Podcast Apple Podcasts